Emergent BioSolutions Inc. (EBS)
USD 8.16
(-7.17%)
USD 8.16
(-7.17%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.18 Billion USD | -33.53% |
| 2022 | 1.78 Billion USD | 33.1% |
| 2021 | 1.34 Billion USD | -6.7% |
| 2020 | 1.43 Billion USD | 15.75% |
| 2019 | 1.24 Billion USD | 1.83% |
| 2018 | 1.21 Billion USD | 671.88% |
| 2017 | 157.86 Million USD | -57.78% |
| 2016 | 373.9 Million USD | -2.52% |
| 2015 | 383.57 Million USD | -2.16% |
| 2014 | 392.06 Million USD | 185.21% |
| 2013 | 137.46 Million USD | 12.58% |
| 2012 | 122.1 Million USD | -6.17% |
| 2011 | 130.13 Million USD | 2.67% |
| 2010 | 126.75 Million USD | 25.66% |
| 2009 | 100.87 Million USD | 10.32% |
| 2008 | 91.43 Million USD | -10.66% |
| 2007 | 102.34 Million USD | 2.57% |
| 2006 | 99.78 Million USD | 145.8% |
| 2005 | 40.59 Million USD | -11.95% |
| 2004 | 46.1 Million USD | 0.0% |
| 2002 | 18.63 Million USD | -67.71% |
| 2001 | 57.71 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 1.12 Billion USD | -1.1% |
| 2024 Q1 | 1.13 Billion USD | -3.87% |
| 2023 Q1 | 1.74 Billion USD | -2.04% |
| 2023 Q3 | 1.19 Billion USD | -2.18% |
| 2023 Q2 | 1.22 Billion USD | -30.03% |
| 2023 FY | 1.18 Billion USD | -33.53% |
| 2023 Q4 | 1.18 Billion USD | -0.86% |
| 2022 FY | 1.78 Billion USD | 33.1% |
| 2022 Q2 | 1.22 Billion USD | 1.42% |
| 2022 Q1 | 1.2 Billion USD | -10.07% |
| 2022 Q3 | 1.45 Billion USD | 19.39% |
| 2022 Q4 | 1.78 Billion USD | 22.23% |
| 2021 Q2 | 1.37 Billion USD | -0.42% |
| 2021 Q1 | 1.37 Billion USD | -4.1% |
| 2021 Q4 | 1.34 Billion USD | -0.36% |
| 2021 Q3 | 1.34 Billion USD | -1.95% |
| 2021 FY | 1.34 Billion USD | -6.7% |
| 2020 Q4 | 1.43 Billion USD | 5.23% |
| 2020 FY | 1.43 Billion USD | 15.75% |
| 2020 Q1 | 1.2 Billion USD | -2.97% |
| 2020 Q2 | 1.26 Billion USD | 5.27% |
| 2020 Q3 | 1.36 Billion USD | 7.69% |
| 2019 Q2 | 1.33 Billion USD | 14.27% |
| 2019 Q1 | 1.16 Billion USD | -4.31% |
| 2019 FY | 1.24 Billion USD | 1.83% |
| 2019 Q3 | 1.29 Billion USD | -2.52% |
| 2019 Q4 | 1.24 Billion USD | -4.47% |
| 2018 FY | 1.21 Billion USD | 671.88% |
| 2018 Q1 | 187.18 Million USD | 18.58% |
| 2018 Q2 | 200.54 Million USD | 7.14% |
| 2018 Q4 | 1.21 Billion USD | 488.72% |
| 2018 Q3 | 206.97 Million USD | 3.21% |
| 2017 Q4 | 157.86 Million USD | -56.21% |
| 2017 Q2 | 349.88 Million USD | 2.54% |
| 2017 FY | 157.86 Million USD | -57.78% |
| 2017 Q1 | 341.22 Million USD | -8.74% |
| 2017 Q3 | 360.49 Million USD | 3.03% |
| 2016 Q3 | 384.4 Million USD | 0.16% |
| 2016 FY | 373.9 Million USD | -2.52% |
| 2016 Q4 | 373.9 Million USD | -2.73% |
| 2016 Q2 | 383.79 Million USD | 4.03% |
| 2016 Q1 | 368.91 Million USD | -3.82% |
| 2015 Q4 | 383.57 Million USD | 3.32% |
| 2015 Q2 | 381.07 Million USD | 0.29% |
| 2015 Q1 | 379.96 Million USD | -3.08% |
| 2015 FY | 383.57 Million USD | -2.16% |
| 2015 Q3 | 371.23 Million USD | -2.58% |
| 2014 Q2 | 349.48 Million USD | 1.08% |
| 2014 FY | 392.06 Million USD | 185.21% |
| 2014 Q3 | 356.15 Million USD | 1.91% |
| 2014 Q1 | 345.75 Million USD | 151.52% |
| 2014 Q4 | 392.06 Million USD | 10.08% |
| 2013 Q1 | 102.58 Million USD | -15.99% |
| 2013 Q3 | 128.6 Million USD | 20.72% |
| 2013 Q2 | 106.53 Million USD | 3.85% |
| 2013 Q4 | 137.46 Million USD | 6.89% |
| 2013 FY | 137.46 Million USD | 12.58% |
| 2012 FY | 122.1 Million USD | -6.17% |
| 2012 Q2 | 104.61 Million USD | 1.97% |
| 2012 Q3 | 111.61 Million USD | 6.69% |
| 2012 Q4 | 122.1 Million USD | 9.4% |
| 2012 Q1 | 102.59 Million USD | -21.17% |
| 2011 Q2 | 112.75 Million USD | 0.36% |
| 2011 FY | 130.13 Million USD | 2.67% |
| 2011 Q1 | 112.35 Million USD | -11.36% |
| 2011 Q3 | 128.45 Million USD | 13.93% |
| 2011 Q4 | 130.13 Million USD | 1.31% |
| 2010 FY | 126.75 Million USD | 25.66% |
| 2010 Q2 | 83.7 Million USD | -10.64% |
| 2010 Q1 | 93.67 Million USD | -7.14% |
| 2010 Q4 | 126.75 Million USD | 45.29% |
| 2010 Q3 | 87.24 Million USD | 4.23% |
| 2009 Q1 | 91 Million USD | -0.48% |
| 2009 Q4 | 100.87 Million USD | 27.01% |
| 2009 FY | 100.87 Million USD | 10.32% |
| 2009 Q3 | 79.42 Million USD | -17.26% |
| 2009 Q2 | 95.98 Million USD | 5.47% |
| 2008 Q3 | 94.56 Million USD | -2.31% |
| 2008 Q2 | 96.8 Million USD | 1.85% |
| 2008 Q1 | 95.04 Million USD | -7.14% |
| 2008 FY | 91.43 Million USD | -10.66% |
| 2008 Q4 | 91.43 Million USD | -3.31% |
| 2007 Q4 | 102.34 Million USD | 22.93% |
| 2007 FY | 102.34 Million USD | 2.57% |
| 2007 Q2 | 66.97 Million USD | 1.68% |
| 2007 Q1 | 65.87 Million USD | -33.98% |
| 2007 Q3 | 83.25 Million USD | 24.31% |
| 2006 FY | 99.78 Million USD | 145.8% |
| 2006 Q4 | 99.78 Million USD | 34.71% |
| 2006 Q3 | 74.07 Million USD | 0.0% |
| 2005 Q4 | 40.59 Million USD | 0.0% |
| 2005 FY | 40.59 Million USD | -11.95% |
| 2004 FY | 46.1 Million USD | 0.0% |
| 2004 Q4 | 46.1 Million USD | 0.0% |
| 2002 FY | 18.63 Million USD | -67.71% |
| 2001 Q4 | 1.34 Billion USD | 0.0% |
| 2001 FY | 57.71 Million USD | 0.0% |
| 2000 Q4 | 1.78 Billion USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 3.45 Billion USD | 65.66% |
| Bausch Health Companies Inc. | 27.43 Billion USD | 95.678% |
| Catalent, Inc. | 6.14 Billion USD | 80.719% |
| Elanco Animal Health Incorporated | 8.13 Billion USD | 85.433% |
| Perrigo Company plc | 6.04 Billion USD | 80.375% |
| Teva Pharmaceutical Industries Limited | 35.35 Billion USD | 96.646% |
| Zoetis Inc. | 9.29 Billion USD | 87.245% |